---
title: 'Research Daily Summary: What Happened on November 10, 2026'
headline: Tu-stroma outperformed CA125 in a study of early ovarian cancer
description: Researchers found the blood-based RNA marker distinguished premalignant
disease from controls and benign masses, but say it needs prospective testing.
url: https://thebench.bio/news/research/2026-11-10
topic: research
date: '2026-11-10'
covers:
- '2026-11-10'
date_published: '2026-11-10T12:04:23Z'
date_modified: '2026-11-10T12:04:23Z'
tags:
- Research
sources: 1
publisher: TheBench.Bio
---
# Research Daily Summary: What Happened on November 10, 2026
**Tu-stroma outperformed CA125 in a study of early ovarian cancer**
Researchers found the blood-based RNA marker distinguished premalignant disease from controls and benign masses, but say it needs prospective testing.
## Today in brief
In a study of 506 people, serum Tu-stroma distinguished a premalignant ovarian lesion from controls and benign masses better than CA125, though the authors say prospective testing is needed. [1]
## The day in numbers
- **0.99 vs. 0.59**: Area under the curve for Tu-stroma and CA125, respectively, when distinguishing premalignant lesions from controls. [1]
- **506**: People included in the study of serum Tu-stroma across normal, benign, premalignant and cancer groups. [1]
## Also published
- [Peek behind the paper | Performance of microarray genotyping and massively parallel sequencing for dense SNP profiling of challenged skeletal remains](), BioTechniques
- [Adjusting for Tumor Mutations: Q&A with Dr. Brian Corgiat](), Pharmaceutical Executive
- [A novel candidate biomarker for detecting premalignant and early ovarian cancer](), Nature Medicine
- [Effective Methods of Accurately Measuring Tumors](), Pharmaceutical Executive
## Sources
1. [Blood-based RNA biomarker for the early detection of ovarian cancer](), Nature Medicine, 2026-11-10
---
TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.
[1]: